Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account as of June 30, 2019: €104,740.61, 43,401 shares.
H1 2019 results validate the company’s 2018 strategic refocus. During the period, revenues increased by 19,6% to reach €4 million (€3.4 million in H1 2018). Net new booking reached €11 million and order backlog increased by 30% to €30.7 million (€23.7 million as of December 31, 2018). Cash and cash equivalents expected to be approximatively €7.9 million as of June 30, 2019, with significantly reduced burn rate.
AG Mednet and Median Technologies Partnership Supports Global Clinical Trials Portfolio, Including Extensive Programs in China
Median Technologiesand AG Mednet have renewed their partnership to use AG Mednet’s global infrastructure for the collection, QC and delivery of medical images and ancillary data in support current and future clinical trials and programs. Median provides solutions and services for medical image analysis and management in oncology trials globally. AG Mednet works with global CROs, providing technology solutions for clinical trial adjudication and imaging.
Disclosure of total number of voting rights and number of shares in the capital as of June 30, 2019 pursuant to article L-223-8 II of the French “Code de Commerce” and 223-16 of the AMF’s General Regulations